You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Policy & Regulation
Brukinsa Approved in the US for Chronic Lymphocytic Leukemia
25 January 2023 - - The US Food and Drug Administration has approved China-based biotechnology company BeiGene's (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235) Bruton's tyrosine kinase inhibitor Brukinsa (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, the company said.
The US approval is based on two global Phase 3 clinical trials demonstrating superior efficacy and a favorable safety profile for Brukinsa in CLL:
With a median follow-up of 26.2 months in the SEQUOIA trial, Brukinsa demonstrated a significant PFS benefit versus bendamustine plus rituximab, (HR 0.42, [95% CI: 0.28, 0.63], P
The US approval is based on two global Phase 3 clinical trials demonstrating superior efficacy and a favorable safety profile for Brukinsa in CLL:
With a median follow-up of 26.2 months in the SEQUOIA trial, Brukinsa demonstrated a significant PFS benefit versus bendamustine plus rituximab, (HR 0.42, [95% CI: 0.28, 0.63], P
Login
Related Headlines
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
AbbVie agrees to acquire Capstan Therapeutics
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes